Arrowhead Pharmaceuticals, Inc.
ARWRNASDAQHealthcare● Active
$73.66
+$0.57(+0.78%)
Market Cap$10.4B
P/E Ratio—
52W High$82.26
52W Low$14.3
Arrowhead Pharmaceuticals, Inc. (ARWR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ARWR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.83B | $0.00B | $0.24B | $0.24B | $0.14B |
| Cost of Revenue | $0.00B | $0.02B | $0.01B | $0.01B | $0.00B |
| Gross Profit | $0.83B | ($0.02B) | $0.23B | $0.23B | $0.00B |
| Gross Margin %(computed) | 100.00% | -423.66% | 94.81% | 95.72% | 0.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.61B | $0.49B | $0.34B | $0.29B | $0.20B |
| G&A Expenses | $0.12B | $0.10B | $0.09B | $0.12B | $0.08B |
| Total Operating Expenses | $0.73B | $0.59B | $0.43B | $0.41B | $0.28B |
| Operating Income | $0.10B | ($0.60B) | ($0.21B) | ($0.18B) | ($0.15B) |
| Operating Margin %(computed) | 11.86% | — | -85.16% | -73.39% | -107.77% |
| Interest Income | $0.04B | $0.02B | $0.02B | $0.01B | $0.01B |
| Interest Expense | $0.09B | $0.03B | $0.02B | $0.00B | $0.00B |
| Income Before Tax | $0.05B | ($0.61B) | ($0.21B) | ($0.17B) | ($0.14B) |
| Income Tax Expense | $0.02B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.00B) | ($0.60B) | ($0.21B) | ($0.18B) | ($0.14B) |
| Net Margin %(computed) | -0.20% | — | -85.27% | -72.39% | -101.85% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.01 | $-5.00 | $-1.91 | $-1.67 | $-1.36 |
| Wtd Avg Shares | 0.13B | 0.12B | 0.11B | 0.11B | 0.10B |
| EBITDA | $0.16B | ($0.56B) | ($0.18B) | ($0.16B) | ($0.13B) |
| EBITDA Margin %(computed) | 19.87% | — | -72.97% | -66.72% | -95.87% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Arrowhead Pharmaceuticals, Inc. data
About Arrowhead Pharmaceuticals, Inc. (ARWR) Income Statement
Arrowhead Pharmaceuticals, Inc. (ARWR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ARWR reported revenue of $0.83B, gross profit of $0.83B (gross margin 100.00%), and net income of ($0.00B) — a net profit margin of -0.20%.
Frequently asked questions
ARWR · 4 questionsArrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $0.83B for 2025, up 23258.2% year-over-year.
ARWR revenueARWR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08